Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Longitudinal assessment of interstitial lung disease in single lung transplant recipients with scleroderma.

Hinze AM, Lin CT, Hussien AF, Perin J, Venado A, Golden JA, Boin F, Brown RH, Wise RA, Wigley FM.

Rheumatology (Oxford). 2019 Aug 27. pii: kez341. doi: 10.1093/rheumatology/kez341. [Epub ahead of print]

PMID:
31504916
2.

Regulatory T cells in skin are uniquely poised to suppress profibrotic immune responses.

Kalekar LA, Cohen JN, Prevel N, Sandoval PM, Mathur AN, Moreau JM, Lowe MM, Nosbaum A, Wolters PJ, Haemel A, Boin F, Rosenblum MD.

Sci Immunol. 2019 Sep 6;4(39). pii: eaaw2910. doi: 10.1126/sciimmunol.aaw2910.

PMID:
31492709
3.

Clinical and Molecular Phenotyping in Scleromyxedema Pre- and Post-Treatment with Intravenous Immunoglobulin.

Mecoli CA, Talbot CC Jr, Fava A, Cheadle C, Boin F, Wigley FM, Hummers LK.

Arthritis Care Res (Hoboken). 2019 Apr 22. doi: 10.1002/acr.23908. [Epub ahead of print]

PMID:
31008568
4.

Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report.

Pauling JD, Frech TM, Hughes M, Gordon JK, Domsic RT, Anderson ME, Ingegnoli F, McHugh NJ, Johnson SR, Hudson M, Boin F, Ong VH, Matucci-Cerinic M, Altorok N, Scolnik M, Nikpour M, Shah A, Pope JE, Khanna D, Herrick AL.

J Scleroderma Relat Disord. 2018 Oct;3(3):249-252. doi: 10.1177/2397198318774307. Epub 2018 May 24.

5.

Vascular complications in systemic sclerosis: a prospective cohort study.

Mecoli CA, Shah AA, Boin F, Wigley FM, Hummers LK.

Clin Rheumatol. 2018 Sep;37(9):2429-2437. doi: 10.1007/s10067-018-4148-5. Epub 2018 May 26.

6.

Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans.

Gourh P, Remmers EF, Boyden SE, Alexander T, Morgan ND, Shah AA, Mayes MD, Doumatey A, Bentley AR, Shriner D, Domsic RT, Medsger TA Jr, Steen VD, Ramos PS, Silver RM, Korman B, Varga J, Schiopu E, Khanna D, Hsu V, Gordon JK, Saketkoo LA, Gladue H, Kron B, Criswell LA, Derk CT, Bridges SL Jr, Shanmugam VK, Kolstad KD, Chung L, Jan R, Bernstein EJ, Goldberg A, Trojanowski M, Kafaja S, Maksimowicz-McKinnon KM, Mullikin JC, Adeyemo A, Rotimi C, Boin F, Kastner DL, Wigley FM.

Arthritis Rheumatol. 2018 Oct;70(10):1654-1660. doi: 10.1002/art.40541. Epub 2018 Aug 29.

7.

Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database.

Morgan ND, Shah AA, Mayes MD, Domsic RT, Medsger TA Jr, Steen VD, Varga J, Carns M, Ramos PS, Silver RM, Schiopu E, Khanna D, Hsu V, Gordon JK, Gladue H, Saketkoo LA, Criswell LA, Derk CT, Trojanowski MA, Shanmugam VK, Chung L, Valenzuela A, Jan R, Goldberg A, Remmers EF, Kastner DL, Wigley FM, Gourh P, Boin F.

Medicine (Baltimore). 2017 Dec;96(51):e8980. doi: 10.1097/MD.0000000000008980.

8.

Flow cytometric discrimination of seven lineage markers by using two fluorochromes.

Boin F, Giardino Torchia ML, Borrello I, Noonan KA, Neil M, Soloski MJ, Cimbro R.

PLoS One. 2017 Nov 30;12(11):e0188916. doi: 10.1371/journal.pone.0188916. eCollection 2017.

9.

PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis.

Sacchetti C, Bai Y, Stanford SM, Di Benedetto P, Cipriani P, Santelli E, Piera-Velazquez S, Chernitskiy V, Kiosses WB, Ceponis A, Kaestner KH, Boin F, Jimenez SA, Giacomelli R, Zhang ZY, Bottini N.

Nat Commun. 2017 Oct 20;8(1):1060. doi: 10.1038/s41467-017-01168-1.

10.

Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.

Morisset J, Vittinghoff E, Elicker BM, Hu X, Le S, Ryu JH, Jones KD, Haemel A, Golden JA, Boin F, Ley B, Wolters PJ, King TE Jr, Collard HR, Lee JS.

Chest. 2017 Nov;152(5):999-1007. doi: 10.1016/j.chest.2017.06.009. Epub 2017 Jun 16.

11.

Lung Transplantation in Patients With Systemic Sclerosis.

Shah RJ, Boin F.

Curr Rheumatol Rep. 2017 May;19(5):23. doi: 10.1007/s11926-017-0650-z. Review.

PMID:
28386760
12.

Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity.

Lofgren S, Hinchcliff M, Carns M, Wood T, Aren K, Arroyo E, Cheung P, Kuo A, Valenzuela A, Haemel A, Wolters PJ, Gordon J, Spiera R, Assassi S, Boin F, Chung L, Fiorentino D, Utz PJ, Whitfield ML, Khatri P.

JCI Insight. 2016 Dec 22;1(21):e89073. doi: 10.1172/jci.insight.89073.

13.

Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma.

Fava A, Cimbro R, Wigley FM, Liu QR, Rosen A, Boin F.

Arthritis Res Ther. 2016 May 4;18(1):99. doi: 10.1186/s13075-016-0993-2.

14.

A methodology for exploring biomarker--phenotype associations: application to flow cytometry data and systemic sclerosis clinical manifestations.

Huang H, Fava A, Guhr T, Cimbro R, Rosen A, Boin F, Ellis H.

BMC Bioinformatics. 2015 Sep 15;16:293. doi: 10.1186/s12859-015-0722-x.

15.

Association of Acroosteolysis With Enhanced Osteoclastogenesis and Higher Blood Levels of Vascular Endothelial Growth Factor in Systemic Sclerosis.

Park JK, Fava A, Carrino J, Del Grande F, Rosen A, Boin F.

Arthritis Rheumatol. 2016 Jan;68(1):201-9. doi: 10.1002/art.39424.

16.

The role of the acquired immune response in systemic sclerosis.

Chizzolini C, Boin F.

Semin Immunopathol. 2015 Sep;37(5):519-28. doi: 10.1007/s00281-015-0509-1. Epub 2015 Jul 8. Review.

PMID:
26152639
17.

Spectrum of Muscle Histopathologic Findings in Forty-Two Scleroderma Patients With Weakness.

Paik JJ, Wigley FM, Lloyd TE, Corse AM, Casciola-Rosen L, Shah AA, Boin F, Hummers LK, Mammen AL.

Arthritis Care Res (Hoboken). 2015 Oct;67(10):1416-25. doi: 10.1002/acr.22620.

18.

Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis.

Poelman CL, Hummers LK, Wigley FM, Anderson C, Boin F, Shah AA.

J Rheumatol. 2015 Feb;42(2):236-42. doi: 10.3899/jrheum.140833. Epub 2014 Nov 29.

19.

Oxidative stress-dependent activation of collagen synthesis is induced in human pulmonary smooth muscle cells by sera from patients with scleroderma-associated pulmonary hypertension.

Boin F, Erre GL, Posadino AM, Cossu A, Giordo R, Spinetti G, Passiu G, Emanueli C, Pintus G.

Orphanet J Rare Dis. 2014 Aug 1;9:123. doi: 10.1186/s13023-014-0123-7.

20.

Association of the autoimmune disease scleroderma with an immunologic response to cancer.

Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, Boin F, Fava A, Thoburn C, Kinde I, Jiao Y, Papadopoulos N, Kinzler KW, Vogelstein B, Rosen A.

Science. 2014 Jan 10;343(6167):152-7. doi: 10.1126/science.1246886. Epub 2013 Dec 5.

21.

Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature.

Gelber AC, Manno RL, Shah AA, Woods A, Le EN, Boin F, Hummers LK, Wigley FM.

Medicine (Baltimore). 2013 Jul;92(4):191-205. doi: 10.1097/MD.0b013e31829be125. Review.

22.

The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis.

Cottrell TR, Wise RA, Wigley FM, Boin F.

Ann Rheum Dis. 2014 Jun;73(6):1060-6. doi: 10.1136/annrheumdis-2012-202849. Epub 2013 Apr 20.

23.

Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion.

Shah AA, Schiopu E, Hummers LK, Wade M, Phillips K, Anderson C, Wise R, Boin F, Seibold JR, Wigley F, Rollins KD.

Arthritis Res Ther. 2013 Apr 18;15(2):R54. doi: 10.1186/ar4216.

24.

Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.

Fava A, Wung PK, Wigley FM, Hummers LK, Daya NR, Ghazarian SR, Boin F.

Arthritis Care Res (Hoboken). 2012 Jun;64(6):925-9. doi: 10.1002/acr.21622. Epub 2012 Jan 24.

25.

Antibodies recognising sulfated carbohydrates are prevalent in systemic sclerosis and associated with pulmonary vascular disease.

Grader-Beck T, Boin F, von Gunten S, Smith D, Rosen A, Bochner BS.

Ann Rheum Dis. 2011 Dec;70(12):2218-24. doi: 10.1136/ard.2011.153130. Epub 2011 Aug 26.

26.

Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis.

Le EN, Wigley FM, Shah AA, Boin F, Hummers LK.

Ann Rheum Dis. 2011 Jun;70(6):1104-7. doi: 10.1136/ard.2010.142000. Epub 2011 Mar 6.

27.

Immunotherapy of systemic sclerosis.

Manno R, Boin F.

Immunotherapy. 2010 Nov;2(6):863-78. doi: 10.2217/imt.10.69. Review.

28.

Resolution of pansclerotic morphea after treatment with antithymocyte globulin.

Song P, Gocke C, Wigley FM, Boin F.

Nat Rev Rheumatol. 2009 Sep;5(9):513-6. doi: 10.1038/nrrheum.2009.159.

PMID:
19710673
29.

The "tank top sign": a unique pattern of skin fibrosis seen in pansclerotic morphea.

Sherber NS, Boin F, Hummers LK, Wigley FM.

Ann Rheum Dis. 2009 Sep;68(9):1511-2. doi: 10.1136/ard.2008.102723. No abstract available.

PMID:
19674989
30.

Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients.

Boin F, Franchini S, Colantuoni E, Rosen A, Wigley FM, Casciola-Rosen L.

Arthritis Rheum. 2009 Aug;60(8):2480-9. doi: 10.1002/art.24684.

31.

Connective tissue diseases: Immunosuppressive therapy in SSc: what is the target?

Boin F, Wigley F.

Nat Rev Rheumatol. 2009 Jul;5(7):357-8. doi: 10.1038/nrrheum.2009.108. No abstract available.

PMID:
19568247
32.

Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera.

Loizos N, Lariccia L, Weiner J, Griffith H, Boin F, Hummers L, Wigley F, Kussie P.

Arthritis Rheum. 2009 Apr;60(4):1145-51. doi: 10.1002/art.24365.

33.

T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease.

Boin F, De Fanis U, Bartlett SJ, Wigley FM, Rosen A, Casolaro V.

Arthritis Rheum. 2008 Apr;58(4):1165-74. doi: 10.1002/art.23406.

34.

Scleroderma-like fibrosing disorders.

Boin F, Hummers LK.

Rheum Dis Clin North Am. 2008 Feb;34(1):199-220; ix. doi: 10.1016/j.rdc.2007.11.001. Review.

35.

Autoimmunity in systemic sclerosis: current concepts.

Boin F, Rosen A.

Curr Rheumatol Rep. 2007 May;9(2):165-72. Review.

PMID:
17502048
36.

Churg-Strauss syndrome presenting with salivary gland enlargement and respiratory distress.

Boin F, Sciubba JJ, Stone JH.

Arthritis Rheum. 2006 Feb 15;55(1):167-70. No abstract available.

37.

Evaluation of topoisomerase-1-specific CD8+ T-cell response in systemic sclerosis.

Boin F, Wigley FM, Schneck JP, Oelke M, Rosen A.

Ann N Y Acad Sci. 2005 Dec;1062:137-45.

PMID:
16461796
38.

Understanding, assessing and treating Raynaud's phenomenon.

Boin F, Wigley FM.

Curr Opin Rheumatol. 2005 Nov;17(6):752-60. Review.

PMID:
16224254
39.

Role of CREB transcription factor in c-fos activation in natural killer cells.

Ponti C, Gibellini D, Boin F, Melloni E, Manzoli FA, Cocco L, Zauli G, Vitale M.

Eur J Immunol. 2002 Dec;32(12):3358-65.

40.

Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor.

Maes M, Bocchio Chiavetto L, Bignotti S, Battisa Tura GJ, Pioli R, Boin F, Kenis G, Bosmans E, de Jongh R, Altamura CA.

Schizophr Res. 2002 Apr 1;54(3):281-91.

PMID:
11950553
41.

Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia.

Bocchio Chiavetto L, Boin F, Zanardini R, Popoli M, Michelato A, Bignotti S, Tura GB, Gennarelli M.

Biol Psychiatry. 2002 Mar 15;51(6):480-4.

PMID:
11922883
42.

Association between -G308A tumor necrosis factor alpha gene polymorphism and schizophrenia.

Boin F, Zanardini R, Pioli R, Altamura CA, Maes M, Gennarelli M.

Mol Psychiatry. 2001 Jan;6(1):79-82.

43.

Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics.

Maes M, Bocchio Chiavetto L, Bignotti S, Battisa Tura G, Pioli R, Boin F, Kenis G, Bosmans E, de Jongh R, Lin A, Racagni G, Altamura CA.

Eur Neuropsychopharmacol. 2000 Mar;10(2):119-24.

PMID:
10706993
44.

HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment.

Altamura AC, Boin F, Maes M.

Eur Neuropsychopharmacol. 1999 Dec;10(1):1-4. Review.

PMID:
10647089
45.

HLA expression in type II mixed cryoglobulinemia and chronic hepatitis C virus.

Ossi E, Bordin MC, Businaro MA, Marson P, Bonadonna P, Chiaramonte M, Boin F, Valenti MT, Fagiolo U.

Clin Exp Rheumatol. 1995 Nov-Dec;13 Suppl 13:S91-3.

PMID:
8730485

Supplemental Content

Support Center